Streetbeat News

MAIA

MAIA Biotechnology, Inc.

https://www.MAIABiotech.com

Industry

Biotechnology

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Open

1.59

Mkt cap

41M

Volume

38K

High

1.63

P/E Ratio

-1.16

52-wk high

5.99

Low

1.55

Div yield

N/A

52-wk low

1.46

SAP SE (NYSE:SAP) shares rose 5.9% in pre-market trading despite missing earnings and sales estimates for Q2. Other notable pre-market movers include Nature’s Miracle Holding Inc. (NASDAQ:NMHI), Volato Group, Inc. (NYSE:SOAR), and Frequency Electronics, Inc. (NASDAQ:FEIM) among gainers, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ) and MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) among losers.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 9:29 am

MAIA Biotechnology reports positive Phase 2 results for its lung cancer treatment THIO, showing safety, efficacy, and ongoing benefits in patients with advanced non-small cell lung cancer (NSCLC). The treatment, combined with cemiplimab (Libtayo®), has been well tolerated with lower toxicity compared to standard treatments.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:12 am

GameStop shares fell over 22% after releasing worse-than-expected Q1 results and filing to sell up to 75 million shares. The company reported net sales of $881.8 million, missing the consensus estimate of $995.3 million, and a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share. Other stocks moving significantly include Trinity Place Holdings, Leafly Holdings, Venus Concept, Asensus Surgical, Faraday Future, Geron Corporation, and more.

Portfolio Pulse from Avi Kapoor

June 07, 2024 | 5:07 pm

MAIA Biotechnology has announced the validation of clinical and regulatory pathways for its telomere-targeting cancer therapies following the FDA approval of Geron's Imetelstat. This development is significant for MAIA's future prospects in cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 4:31 pm

MAIA Biotechnology has announced significant year-to-date achievements, including clinical progress of its lead candidate THIO, a first-in-class cancer telomere targeting agent for non-small cell lung cancer (NSCLC). The company has secured over $12 million in funding, with $7.4 million raised in Q2'24. THIO has shown exceptional efficacy in Phase 2 clinical trials, with a 38% overall response rate and a median progression-free survival of 5.5 months, outperforming current standard-of-care treatments.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:08 pm

The article highlights significant intraday movements in health care stocks on Wednesday. Notable gainers include ENDRA Life Sciences (NDRA), Rezolute (RZLT), Bright Green (BGXX), Champions Oncology (CSBR), Kineta (KA), and CVRx (CVRX). On the losing side, SILO Pharma (SILO), Concord Medical Services (CCM), FibroBiologics (FBLG), Cue Health (HLTH), GH Research (GHRS), and MAIA Biotechnology (MAIA) experienced notable declines.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 4:31 pm

The article highlights the performance of various health care stocks during Tuesday's after-market session. Concord Medical Services (NYSE:CCM) saw a significant increase of 131%, while other stocks like Calidi Biotherapeutics (AMEX:CLDI) and Anitra (AMEX:AZTR) also experienced gains. On the losing side, BiomX (AMEX:PHGE) and SunLink Health Systems (AMEX:SSY) saw notable declines.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 8:31 pm

MAIA Biotechnology shares are trading lower after the company reported new clinical data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 4:46 pm

MAIA Biotechnology announced that its clinical trial data for THIO shows efficacy in treating non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:42 pm

MAIA Biotechnology is set to present at the BIO International Convention 2024, which could provide significant exposure and potential partnerships for the company.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.